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Computational modeling, pharmacophore generation, and virtual screening. 
There was no available structure, for any neurotrophin-Trk pair-
ing, of the binding of the β-loops of interest to the receptor, and 

















































































Pharmacophore and LM22A compound structures. (A) Inset: Variable loop regions of a human BDNF monomer extracted from the crystal-
lographically determined structure of a BDNF-NT3 heterodimer (56). The larger image shows the loop IIb (sequence SKGQL) pharmacophore 
hypothesis, as described in the text. Red, hydrogen bond donor; green, hydrogen bond acceptor. (B) Structures of the 4 LM22A compounds 
chosen for these studies. Compounds are abbreviated as #1–#4 in subsequent figures.
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LM22A compounds specifically activate TrkB. To examine the effects 












Neurotrophic activities of LM22A compounds. (A) Fluorescence photomicrographs (original magnification, ×40) of GAP43-immunostained E16 
mouse hippocampal neuronal cultures treated with culture medium (CM), BDNF, or LM22A-4 (#4) for 48 hours. (B–E) Neuron survival dose-
response curves for BDNF and LM22A compounds. Counts were normalized to survival achieved with 20 ng/ml (~0.7 nM) BDNF. For BDNF, 
survival values for each concentration were derived from n = 29–32 wells obtained from 12 separate experiments; for LM22A-1, -2, and -3, values 
for each concentration were derived from n = 11–19 wells obtained from 6 separate experiments; for LM22A-4, values for each concentration 
were derived from n = 13–21 wells obtained from 8 separate experiments. White circles, compound responses; black circles, BDNF responses 
(F) Comparison of survival curves from all compounds and BDNF. (G) Quantitation of the fraction of TUNEL-positive/DAPI-staining cells dem-
onstrates that LM22A compounds decrease the number of TUNEL-positive cells to a degree similar to that of BDNF. A total of n = 93–95 fields 
per condition derived from 3 separate assays were counted. (H) Survival analysis of E16 hippocampal neurons treated with nonimmune serum 
(Control) or antibody to BDNF (Ab; 1:400) and BDNF (0.7 nM) or LM22A compounds (500 nM). Counts made in a total of n = 10–12 wells were 
derived from 5–6 experiments. (I) Survival of E16 hippocampal neurons treated with BDNF alone (0.7 nM), LM22A-4 alone (500 nM), or BDNF 
plus LM22A-4. n = 24–72 wells for each condition derived from 3 experiments were analyzed. *P < 0.05, **P < 0.01, ***P < 0.001.
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LM22A-induced TrkB and downstream signaling activation kinetics: dif-






LM22A compounds function through TrkB. (A) Survival analysis of hippocampal neurons treated with BDNF (0.7 nM) or LM22A compounds 
(500 nM) with or without the Trk inhibitor K252a (200 nM). For BDNF, n = 37 wells derived from 7 experiments; for LM22A-1, -2, and -3, 
n = 17–21 wells derived from 6 experiments; and for LM22A-4, n = 28–57 wells derived from 4 experiments were assessed. (B) Survival 
analysis of hippocampal neurons treated with CM, BDNF (0.7 nM), or LM22A compounds (500 nM) with or without TrkBECD antibody. For 
each condition, n = 37–42 wells derived from 5 experiments were assessed. (C) TUNEL/DAPI analysis of E16 hippocampal neurons treated 
with CM, BDNF (0.7 nM), or LM22A compounds (500 nM) with or without TrkBECD antibody. For each condition, n = 17–31 fields derived 
from 3 experiments were assessed. (D) LM22A compounds or neurotrophic factors were incubated for 60 minutes with NIH-3T3 cells stably 
expressing specific Trk receptors. Western blot analysis (anti–pan-phospho-TrkY490 [p-Trk]) demonstrated that LM22A compounds activated 
TrkB (upper panels) but not TrkA (middle panels) or TrkC (lower panels), while all 3 Trks were activated by their cognate ligands. Activa-
tion patterns of 3 additional independent assays were identical. (E–H) Trk- and p75NTR-specific NIH-3T3 cells were incubated in serum-free 
medium in the presence of the designated ligands for 72–96 hours, and survival was measured using the EnzyLight assay. n = 18–28 wells 
derived from 11–14 experiments. *P < 0.05, **P < 0.01, §P < 0.001.
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LM22A-4 matches BDNF efficacy in preventing neuronal death in 
in vitro models of neurodegenerative diseases. Since the LM22A com-
pounds upregulated fundamental survival/stress resistance mech-
Figure 4
LM22A-4 binds selectively to TrkB. (A) LM22A-4 was incubated with ephrin A5-Fc receptor as a negative control or with TrkBECD-Fc in the 
absence or presence of BDNF (600 pmol). After rinsing of receptor complexes and subsequent ligand elution, LC/MS-MS demonstrated 
readily detectable LM22A-4 binding to TrkBECD-Fc that was blocked by BDNF. Values were derived from n = 3 independent binding studies. 
(B) BDNF (100 nM, black circles) or NGF (100 nM, white squares) was incubated with TrkBECD-Fc-Cy3B (100 nM) and increasing concentra-
tions of LM22A-4; fluorescence anisotropy (<r>) was measured n = 6–9 times in single samples at each concentration. (C–F) NIH-3T3 cells 
expressing TrkB, TrkA, TrkC, or p75NTR as indicated were incubated with increasing concentrations of the indicated neurotrophin in the absence 
(white squares, dashed line) or presence (black circles, solid line) of 100 nM LM22A-4. Symbols represent average fluorescent signal after 
background (i.e., binding to cells lacking expressed receptors) subtraction, as described in Methods. n = 14–18 wells from 7–9 experiments 
at each concentration. Significant rightward shifting of the binding curve by the compound was observed only with TrkB expressing cells. 
*P < 0.05, **P < 0.01, ***P < 0.001.
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Comparison of BDNF’s and LM22A compound’s signaling activation kinetics and dependence of survival on downstream signaling. (A) Left: 
Representative Western blot showing activation of Trk, AKT, and ERK in cultured E16 hippocampal neurons incubated with LM22A-4 at the 
indicated concentrations for 60 minutes. Right: Western blot analyses were quantitated for Trk, AKT, and ERK activation (ratio of p-TrkY490, using 
a pan–phospho-Trk antibody, to total TrkB; p-AKT to total AKT; and p-ERK to total ERK signal). n = 15–18 Western analyses from 4–9 indepen-
dent protein preparations. (B–D) Cultured E16 hippocampal neurons were incubated with BDNF (0.7 nM) or LM22A compounds (500 nM) for 
the indicated times, and quantitative analysis for Trk, AKT, and ERK activation was performed as in A. n = 8–11 Western blot analyses from 4–5 
independent protein preparations. For each Western blot, the activation ratio induced by BDNF at the 10-minute time point was normalized to 1.0 
and the other values adjusted accordingly. (E) E16 hippocampal neurons were incubated with BDNF (0.7 nM) or LM22A compounds (500 nM) 
for 48 hours in the presence or absence of the PI3K inhibitor LY294002 (LY, 10 μM) or the MAPK kinase inhibitor PD98059 (PD, 50 μM). For 
BDNF, n = 33–37 wells derived from 7 experiments were assessed. For LM22A-1, -2, and -3, n = 17–21 wells derived from 6 experiments were 
analyzed. For LM22A-4, n = 28–57 wells derived from 4 experiments were assessed. *P < 0.05, #P < 0.01, §P < 0.001.
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LM22A-4 activates Trk, AKT, and ERK signaling in vivo. LM22A-4 or 
saline control was administered intranasally (0.22 mg/kg/d) to adult 
mice for 7 days. Protein extracts of hippocampus and striatum were 
assessed by Western blot analysis for (A) Trk, (B) AKT, or (C) ERK 
phosphorylation. n = 11 mice for each assay. *P < 0.05.
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LM22A-4 inhibits neuronal death in in vitro neurodegenerative disease models. (A) Six- to 7-DIV hippocampal neurons from E16 mice were 
treated in the absence of Aβ with CM alone or CM + K252a (K) or in the presence of oligomeric Aβ with CM alone, CM + K252a, BDNF (0.7 nM), 
BDNF + K252a, LM22A-4 (500 nM), LM22A-4 + K252a. K252a was used at 200 nM. After 72 hours, cultures were assessed by TUNEL/DAPI 
staining. n = 28–29 fields for each condition derived from a total of 3 experiments. (B) SH-SY5Y human neuroblastoma cells were pretreated for 
3 days in the following conditions: CM alone, CM + K252a, BDNF (0.7 nM), BDNF + K252a, LM22A-4 (500 nM), LM22A-4 + K252a. MPP+ (100 μM) 
was added, and 48 hours later cell survival was assessed by MTT/cell count assay. (C) Six- to 7-DIV striatal neurons from E16 mice were pretreat-
ed for 2 hours in the following conditions: CM, CM + K252a, BDNF (0.7 nM), BDNF + K252a, LM22A-4 (500 nM), LM22A-4 + K252a. QA (7.5 mM) 
was added, and after 24 hours numbers of DARPP-32–positive/total surviving cells was determined. n = 50–100 fields for each condition derived 
from a total 5 experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
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LM22A-4 restores motor learning after TBI. Adult male Sprague-Daw-
ley rats were trained on an accelerating rotarod task and subjected to 
parietal controlled cortical impact injury (filled symbols) or sham sur-
gery (open symbols). Injured animals were treated intranasally with 
vehicle alone or containing LM22A-4 beginning immediately after injury 
then daily for 2 weeks, as indicated. Symbols indicate the mean ± SEM 
of the dwell time on the rod from the average of 2 trials per animal/
week; n = 5 animals for vehicle and sham, and n = 6 for LM22A-4; 
significance was determined by repeated-measures ANOVA and post-
hoc Holm-Sidak analysis. **P < 0.01.
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from  the  lambda,  and  1  mm  from  the  sagittal  suture.  Injury  was 
induced using a computer-controlled electromagnetic  linear motor 
fitted with a slightly rounded 2-mm-diameter impact tip positioned 
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